<DOC>
	<DOCNO>NCT00555152</DOCNO>
	<brief_summary>This randomized phase I/II trial study side effect best dose lapatinib ditosylate see well work treat patient ductal breast carcinoma situ . Lapatinib ditosylate may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Lapatinib Ditosylate Treating Patients With Ductal Breast Carcinoma In Situ</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine whether lapatinib ( lapatinib ditosylate ) therapy dose 1000 mg result statistically significantly low rate proliferation ductal carcinoma situ ( DCIS ) breast cancer cell measure Ki67 compare placebo . II . Determine toxicity profile frequency adverse event woman DCIS breast cancer take lapatinib 1000 mg compare woman take placebo . SECONDARY OBJECTIVES : I . Determine whether lapatinib treatment affect incidence DCIS see time surgical excision . II . Determine whether treatment lapatinib modulate breast tissue histology expression specific biomarkers normal DCIS breast cancer cell . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive lapatinib ditosylate orally ( PO ) daily ( QD ) 2-6 week time surgery . ARM II : Patients receive placebo PO QD 2-6 week time surgery . After completion study treatment , patient follow 4-5 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Participants must premenopausal postmenopausal Participants must diagnosis ductal carcinoma situ make core needle biopsy The DCIS cell must high expression human epidermal growth factor receptor 2 ( erbB2 ) ( 3+ immunohistochemical stain amplification fluorescence situ hybridization [ FISH ] ) , and/or detectable expression epidermal growth factor receptor ( EGFR ) ( 1+ immunohistochemical stain ) All participant must inform investigational nature study must sign give write informed consent accordance institutional federal guideline Individuals diagnosis breast cancer , nonmelanoma skin cancer , cervical cancer situ , early bladder cancer eligible treat chemotherapy , biological therapy , breast radiotherapy breast currently affect DCIS within one year ; addition , individual diagnosis breast cancer may use tamoxifen , raloxifene , antiestrogen compound within three month study day 1 If subject reproductive potential , must agree use reliable contraceptive method sexually abstinent ; subject must fulfill condition begin time start study medication end one month study termination Negative serum pregnancy test ( betahuman chorionic gonadotropin [ HCG ] ) baseline ( within 30 day day 0 ) woman child bear potential Serum creatinine = &lt; 1.5 time institution 's upper limit normal Total bilirubin = &lt; 1.5 time institution 's upper limit normal Serum glutamic oxaloacetic transaminase ( SGOT ) = &lt; 1.5 time institution 's upper limit normal Alkaline phosphatase = &lt; 1.5 time institution 's upper limit normal Albumin = &lt; 1.5 time institution 's upper limit normal White blood cell ( WBC ) &gt; 4.0 k/uL Platelet count &gt; 100,000/uL Hematocrit &gt; 30 % Cardiac ejection fraction within normal limit institution multi gated acquisition scan ( MUGA ) scan normal cardiac ultrasound ( define within upper limit normal [ ULN ] institution ) Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Willingness refrain donate blood others study Individuals ineligible either active cancer prior history malignancy ( e.g. , breast cancer , skin cancer [ basal squamous cell carcinoma ] , cervical cancer situ , early bladder cancer [ preinvasive transitional cell carcinoma bladder ] ) within past five year Participants ineligible currently treat tamoxifen , raloxifene , aromatase inhibitor ( letrozole , anastrozole , exemestane ) Individuals ineligible receive chemotherapy , biological therapy ( e.g. , Herceptin ) , radiotherapy treatment cancer within 1 year receive tamoxifen , raloxifene , letrozole , anastrozole , exemestane therapy within 3 month study day 1 Individuals currently receive anticoagulation therapy ( e.g. , Coumadin ) ineligible Blood urea nitrogen [ BUN ] &gt; 1.5 x ULN Creatinine [ Cr ] &gt; 1.5 x ULN SGOT &gt; 1.5 x ULN Serum glutamate pyruvate transaminase ( SGPT ) &gt; 1.5 x ULN Alkaline phosphatase &gt; 1.5 x ULN Bilirubin &gt; 1.5x ULN Individuals currently participate study investigational drug Pregnancy , lactation unwillingness use reliable contraceptive method woman childbearing potential Severe underlie chronic illness disease , uncontrolled diabetes Individuals know congestive heart disease previous myocardial infarction ineligible Patients take prohibited medication Individuals hypokalemia hypomagnesemia ineligible unless condition correct within normal limit start drug Individuals congenital long QT syndrome baseline QTcF interval &gt; 480 msec electrocardiogram ( EKG ) Individuals take antiarrhythmic , beta blocker , medication may lead QT prolongation Individuals receive cumulative dose anthracycline therapy great 500 mg/m^2 ineligible</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>